Moreover, evodiamine decreased NF-κB activity and expressions of NF-κB-dependent antiapoptotic, proliferative, and metastatic genes in human myeloid leukemia KBM-5 cells, which indicated NF-κB might be another potential target of evodiamine for anti-leukemia therapy [60] (Figure 3). This evidence concerns the gene NFKB1 and leukemia.